The ␤-chemokine receptor CCR5 is considered to be an attractive target for inhibition of macrophagetropic (CCR5-using or R5) HIV-1 replication because individuals having a nonfunctional receptor (a homozygous 32-bp deletion in the CCR5 coding region) are apparently normal but resistant to infection with R5 HIV-1. In this study, we found that TAK-779, a nonpeptide compound with a small molecular weight (M r 531.13), antagonized the binding of RANTES (regulated on activation, normal T cell expressed and secreted) to CCR5-expressing Chinese hamster ovary cells and blocked CCR5-mediated Ca 2؉ signaling at nanomolar concentrations. The inhibition of ␤-chemokine receptors by TAK-779 appeared to be specific to CCR5 because the compound antagonized CCR2b to a lesser extent but did not affect CCR1, CCR3, or CCR4. Consequently, TAK-779 displayed highly potent and selective inhibition of R5 HIV-1 replication without showing any cytotoxicity to the host cells. The compound inhibited the replication of R5 HIV-1 clinical isolates as well as a laboratory strain at a concentration of 1.6-3.7 nM in peripheral blood mononuclear cells, though it was totally inactive against T-cell line-tropic (CXCR4-using or X4) HIV-1.
Progress of combination chemotherapy with HIV-1 reverse transcriptase and protease inhibitors has achieved longsustained suppression of viral replication in HIV-1-infected individuals (1, 2) . However, considering high cost and low compliance of long-term combination chemotherapy (3), it seems still mandatory to discover novel anti-HIV-1 agents with different mechanism of action. The ␤-chemokine receptor CCR5 has been shown to act as a major coreceptor for fusion and entry of macrophage-tropic (CCR5-using or R5) HIV-1 into the host cells (4) (5) (6) (7) (8) . R5 strains are predominant during the asymptomatic stages of HIV-1 infection whereas T-cell linetropic (CXCR4-using or X4) strains become prevalent, concomitant with the decline of CD4 ϩ T cells, in the symptomatic stages (9) (10) (11) . A 32-bp deletion in the CCR5 coding region (CCR5⌬32) generates a nonfunctional receptor, and CCR5⌬32 homozygous individuals are apparently normal but resistant to infection with R5 HIV-1 (12, 13) . Furthermore, a recent study suggests that most of the non-syncytium-inducing clinical isolates use only CCR5 for their infection (11, 14, 15) . Thus, CCR5 is considered to be an attractive target for inhibition of R5 HIV-1 replication. Although the natural ligands for CCR5 [regulated on activation, normal T cell expressed and secreted (RANTES), macrophage inflammatory protein 1␣, and macrophage inflammatory protein 1␤] and their modifications (Met-RANTES and aminooxypentane-RANTES) are known to block R5 HIV-1 infection (16) (17) (18) , nonpeptide CCR5 antagonists have not been identified. In this study, we found TAK-779 ( Fig. 1) , a small molecular weight (M r 531.13) nonpeptide compound, to be a potent CCR5-specific antagonist. The compound inhibited R5 HIV-1 replication at concentrations Ͻ10 nM, although it was totally inactive against X4 HIV-1. Fig. 1 ) was carried out in Takeda Chemical Industries (Osaka) and is described elsewhere (M.S., unpublished work). The CXCR4 antagonist AMD3100 (19, 20) was kindly provided by E. De Clercq (Katholieke Universitiet Leuven, Leuven, Belgium). TAK-779 was dissolved in dimethyl sulfoxide at 20 mM to exclude any antiviral or cytotoxic effect of dimethyl sulfoxide. AMD3100 was dissolved in distilled water.
MATERIALS AND METHODS

Compounds. Synthesis and purification of TAK
Cells and Viruses. The Chinese hamster ovary cells (CHO-K1) and Jurkat cells were purchased from the American Type Culture Collection. The cells were cultured in Ham's F-12 medium (Life Technologies, Gaithersburg, MD) supplemented with 10% FCS and 50 g͞ml gentamycin (Life Technologies). MAGI-CCR5 cells, a HeLa-CD4 line that expresses CCR5 and has an integrated copy of the HIV-1 long terminal repeat-driven ␤-D-galactosidase reporter gene (21) , were obtained through J. Overbaugh of the AIDS Research and Reference Reagent Program, National Institute of Allergy and Infectious Diseases (Bethesda, MD). Four R5 HIV-1 strains (Ba-L, KK, HHA, and CTV) and three X4 HIV-1 strains (III B , SW, and MZ) were used in this study. KK, HHA, CTV, SW, and MZ are clinical isolates from infected patients in Japan. Except for III B , all strains were propagated in phytohemagglutinin-stimulated peripheral blood mononuclear cells (PBMCs) obtained from healthy donors. The III B strain was propagated in MT-4 cells (22) . The virus stocks were determined for their p24 antigen levels and were stored at Ϫ80°C until use.
DNA Construct and Transfection. CCR5 cDNA (23, 24) was amplified by PCR from a human spleen cDNA library (Toyobo, Osaka) and was subcloned into the pcDNA3.1 expression vector with human cytomegalovirus promoter (Fu-
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked ''advertisement'' in accordance with 18 U.S.C. §1734 solely to indicate this fact. chelating. Antiviral Assays. The anti-HIV-1 activities of the test compounds were based on the inhibition of virus-induced infectious focus formation in MAGI-CCR5 cells and the reduction of p24 antigen production in PBMCs, as described (25, 26) . In brief, MAGI-CCR5 cells (1 ϫ 10 4 cells per well) were cultured in a microtiter tray. After a 24-h incubation at 37°C, the culture supernatants were replaced with fresh culture media containing the virus (Ϸ300 focus forming units per well) and various concentrations of the test compounds. After a 2-day incubation, the cells were fixed and stained with 5-bromo-4-chloro-3-indolyl-␤-D-galactosidase. The number of infected (blue) cells was counted microscopically. For the PBMC assays, phytohemagglutinin-stimulated PBMCs (2.5 ϫ 10 5 cells per 500 l) were infected with HIV-1 in the presence of various concentrations of the test compounds. The amounts of the virus used for infection were, depending on the replicability of each strain, generally 1-10 ng of p24 per 2.5 ϫ 10 5 cells. After an overnight incubation at 37°C, the cells were washed extensively to remove unadsorbed viral particles and were incubated further with culture media containing the same concentrations of the compounds as those used during viral adsorption. On day 6 after viral infection, the culture supernatants were collected and determined for their p24 antigen levels with a sandwich ELISA kit (Cellular Products). The cytotoxicities of the compounds were evaluated in parallel with their antiviral activities. They were based on the viability and proliferation of mock-infected cells, as determined by the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method (27) . (Fig. 2 A and B) . A lead compound was discovered from the chemical library of Takeda Chemical Industries by high throughput screening based on receptor binding assay using [ (Fig. 2C) . Its 50% inhibitory concentration (IC 50 ) for the binding was 1.4 nM. The compound also blocked the binding of macrophage inflammatory protein 1␣ and macrophage inflammatory protein 1␤ to the cells with an IC 50 of 1.0 nM (data not shown). From competitive binding experiments, the K i value of TAK-779 was estimated to be 1.1 nM. To determine whether the inhibitory effect of TAK-779 on the chemokine binding is specific to CCR5, the activity of TAK-779 was examined in CHO cells stably expressing either CCR1, CCR2b, CCR3, or CCR4. The compound had no effect on the binding of ]-thymus-and activation-regulated chemokine to CCR1, CCR3, and CCR4, respectively (Fig. 3) . Although TAK-779 inhibited the binding of [ 125 I]-monocyte chemotactic protein 1 to CCR2b in CHO͞CCR2b cells, its IC 50 for CCR2b (27 nM) was Ϸ20-fold higher than that for CCR5, indicating that TAK-779 preferentially inhibits CCR5. Furthermore, we also examined the inhibitory effect on the binding of [ 125 I]-stromal cell-derived factor 1␣ to CXCR4 in (Fig. 4A) . Addition of 10 nM TAK-779 did not affect the Ca 2ϩ level but completely abrogated the RANTES-induced increase of intracellular Ca 2ϩ level in CHO͞CCR5 cells, and the effect was dose-dependent (Fig. 4A) . In contrast, the compound did not affect the RANTES-induced Ca 2ϩ mobilization in CHO͞CCR1 cells even at a concentration of 100 nM (Fig. 4B) . These results indicate that TAK-779 selectively blocks the CCR5-mediated Ca 2ϩ -signaling.
RESULTS
TAK-779 Inhibits
TAK-779 Is a Potent and Selective Inhibitor of R5 HIV-1. We evaluated the inhibitory effect of TAK-779 on HIV-1 replication in MAGI-CCR5 cells, which express endogenous CXCR4. As shown in Fig. 5 , TAK-779 completely inhibited R5 HIV-1 (Ba-L strain) replication in MAGI-CCR5 cells at a concentration of 32 nM. Its 50% and 90% effective concentrations (EC 50 and EC 90 ) were 1.2 and 5.7 nM, respectively. However, TAK-779 did not affect X4 HIV-1 (III B strain) replication at concentrations up to 20 M. The 50% cytotoxic concentration (CC 50 ) of TAK-779 for MAGI-CCR5 cells was 51 M (data not shown). Thus, the selectivity index (ratio of CC 50 to EC 50 ) of TAK-779 was 42,500, indicating that the compound is an extremely potent and selective inhibitor of R5 HIV-1 replication. Furthermore, TAK-779 was totally inactive against other X4 HIV-1 (MN and HE strains) or HIV-2 (ROD and EHO strains) in MAGI-CCR5 cells (data not shown). In marked contrast, the specific CXCR4 inhibitor AMD3100 (19, 20) completely inhibited the replication of III B strain at 32 nM, although it was not inhibitory to the replication of Ba-L strain at concentrations up to 100 M (Fig. 5) .
To confirm the anti-HIV-1 activity of TAK-779, the compound was examined for its inhibitory effects on the replication of R5 HIV-1 clinical isolates in PBMCs. As shown in Table 1 , TAK-779 proved to be a highly potent inhibitor of the R5 HIV-1 clinical isolates KK, HHA, and CTV as well as the laboratory strain Ba-L. The EC 50 and EC 90 values for these isolates were 1.6-3.7 nM and 7.5-27 nM, respectively. TAK-779 did not reduce the viability and proliferation of mockinfected PBMCs at concentrations up to 20 M ( Table 1 ), indicating that TAK-779 also had outstanding selectivity in- (Table 1) .
DISCUSSION
The inhibition of chemokine receptors by TAK-779 appears to be specific to CCR5 because it was highly inhibitory to the binding of [ (Fig. 3) . Furthermore, chemokine binding to neither CCR1, CCR3, CCR4, nor CXCR4 was inhibited by the compound. The inhibitory effect of TAK-779 was shown to be selective for CCR5 and not for RANTES because the compound had no effect on [ 125 I]-RANTES binding to CCR1 (Fig.  3) and RANTES-induced Ca 2ϩ mobilization in CHO͞CCR1 cells (Fig. 4) . The specificity of TAK-779 to CCR5 seems extremely important from a chemotherapeutic viewpoint because nonspecific inhibition of ␤-chemokine receptors may generate serious side effects associated with chemokine dysregulation (29) . Although some HIV-1 isolates can use CCR3 as an alternative coreceptor for their entry into the host cells, in particular, macrophages and microglia (30, 31) , the contribution of CCR3 to HIV-1 infection and pathogenesis in vivo has not fully been elucidated.
Unlike RANTES and aminooxypentane-RANTES (32), TAK-779 did not induce the internalization of CCR5 (experiments and data not shown). However, TAK-779 could suppress the binding of the anti-CCR5 mA 45531.111 (R & D Systems) to CHO͞CCR5 cells (experiments and data not shown), suggesting the direct interaction between the compound and CCR5. Because the monoclonal antibody was directed to the second extracellular loop of seven-transmembrane receptor CCR5, TAK-779 may have interaction with this extracellular loop. Alternatively, TAK-779 may induce a conformational change of the second extracellular loop after binding to a different part of CCR5. Of interest, TAK-779 did not inhibit the binding of another anti-CCR5 mAb, 2D7 (PharMingen), to CHO͞CCR5 cells (experiments and data not shown), although 2D7 also recognizes the second extracellular loop of CCR5 (33) . The exact site on CCR5 molecule targeted by the compound remains to be determined.
Another important issue to be considered is the emergence of drug-resistance. It is unlikely that frequent mutations occur in the second extracellular loop of CCR5. However, HIV-1 may be able to acquire the resistance to TAK-779 by amino acid mutations of the viral envelope protein gp120. In fact, X4 HIV-1 resistant to stromal cell-derived factor 1␣ (natural ligand for CXCR4) and AMD3100 recently has been reported (34) . The resistant virus had multiple mutations in gp120 but did not switch chemokine receptor usage. In conclusion, TAK-779 seems to be a promising agent for treatment and prophylaxis of HIV-1 infection. Studies of its toxicology and pharmacokinetics in animals are in progress, aiming at starting its phase I clinical trials in the near future. EC50 and EC90 were defined as the concentrations of TAK-779 required to reduce p24 antigen production in culture supernatants of HIV-1-infected PBMCs by 50 and 90%, respectively. CC50 was defined as the concentration of TAK-779 required to reduce the viability and proliferation of mock-infected PBMCs by 50%. KK, HHA, and CTV strains are R5 HIV-1 clinical isolates whereas SW and MZ strains are X4 HIV-1 clinical isolates. All data represent means Ϯ SEM of at least three separate experiments.
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